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species are the fourth leading cause of nosocomial blood-
stream infections [2]. And although  C. albicans remains 
the leading and the most widespread pathogenic yeast spe-
cies causing a variety of infections, the incidence rates of 
non- C .  albicans Candida infections has increased in recent 
years, including those with intrinsic or acquired resistance 
to azole antifungals [1 – 3]. More recently, infections caused 
by less common yeast species such as  Pichia ,  Rhodotorula , 
 Trichosporon , and  Saccharomyces spp. [4 – 8] and other 
rarely encountered species have been reported [1,9,10]. 
Rapid identifi cation of yeast isolates from clinical samples 
is particularly important to initiate appropriate therapy 
given their variable antifungal susceptibility profi les. How-
ever, this task is complicated by the increasing number of 
emerging pathogenic fungal species that are not included 
 Introduction 
 The incidence of fungal infections has dramatically 
increased in the past several decades. Invasive infections 
caused by yeasts have become a major cause of morbidity 
and mortality in immunodefi cient patients and those receiv-
ing immunosuppressive chemotherapy for cancer and 
organ transplantation [1,2]. In the United States,  Candida 
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 In this study, matrix-assisted laser desorption/ionization time-of-fl ight mass spectrom-
etry (MALDI-TOF MS) was used as a rapid method to identify yeasts isolated from 
patients in Tunisian hospitals. When identifi cation could not be exstablished with this 
procedure, sequencing of the internal transcribed spacer with 5.8S ribosomal DNA 
(rDNA) (ITS1 – 5.8S – ITS2) and D1/D2 domain of large-subunit (LSU rDNA) were 
employed as a molecular approach for species differentiation.  Candida albicans  was the 
dominant species (43.37% of all cases), followed by  C. glabrata (16.55%),  C. parapsi-
losis (13.23%),  C. tropicalis (11.34%),  C. dubliniensis (4.96%), and other species more 
rarely encountered in human diseases such as  C. krusei ,  C. metapsilosis ,  C. lusitaniae , 
 C. kefyr ,  C. palmioleophila ,  C. guilliermondii ,  C. intermedia ,  C. orthopsilosis , and  C. 
utilis . In addition, other yeast species were obtained including  Saccharomyces cerevi-
siae ,  Debaryomyces hansenii (anamorph known as  C. famata ),  Hanseniaspora opuntiae , 
 Kodamaea ohmeri ,  Pichia caribbica (anamorph known as  C. fermentati ),  Trichosporon 
spp. and fi nally a novel yeast species,  C. tunisiensis . The  in vitro antifungal activities of 
fl uconazole and voriconazole were determined by the agar disk diffusion test and Etest, 
while the susceptibility to additional antifungal agents was determined with the Sensi-
titre YeastOne system. Our results showed low incidence of azole resistance in  C. albi-
cans (0.54%),  C. tropicalis (2.08%) and  C. glabrata (4.28%). In addition, caspofungin 
was active against most isolates of the collection with the exception of two  K. ohmeri 
isolates. This is the fi rst report to describe caspofungin resistant isolates of this yeast. 
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in the repertoires of commercially available conventional 
identifi cation kits [11,12] and their identifi cation by con-
ventional methods may be diffi cult and sometimes incon-
clusive. Most often, the widely available methods in routine 
use in clinical laboratories are chromogenic agar media, 
immunological kits and biochemical or enzymatic tests, 
e.g., ID 32C strip or VITEK YST card (bioM é rieux) [13 –
 15]. Due to limited databases, misidentifi cations have been 
reported [10,16,17], thus necessitating more discrimina-
tory technologies. Species identifi cation is also important 
for understanding the epidemiology of fungal infections, 
including trends in species distribution and antifungal sus-
ceptibility patterns. Thus, the identifi cation, taxonomy and 
epidemiological analysis of fungal pathogens are increas-
ingly dependent on modern molecular techniques based on 
PCR amplifi cation of conserved regions of the genome and 
on sequencing the resulting PCR products [10,11,17 – 19]. 
These methods provide high sensitivity and specifi city, but 
their effi ciency is limited by the complexity of the culture 
and isolation procedures. Moreover, they are completely 
dependent on the known genetic sequences of the target 
microorganisms. Additionally, molecular biology tech-
niques require a high level of technical expertise, remain 
expensive, and are therefore not suitable for routine iden-
tifi cation. New approaches are required for the rapid anal-
ysis of microorganisms in clinical microbiology laboratories 
to initiate early and appropriate treatment to improve 
patient care. Among recently developed rapid techniques 
for identifi cation of microorganisms encountered in clini-
cal settings, the use of protein profi les obtained by MAL-
DI-TOF MS directly from growing fungal colonies has 
been successful. The method analyzes the profi les of mac-
romolecules that are obtained from whole microorganisms 
[20]. This new proteomic approach allows rapid and accu-
rate identifi cation of bacteria as well as fungi [12,20 – 27]. 
 Azole antifungals are often the preferred fi rst line agents 
for treatment of invasive fungal infections and have good 
but variable activity against  Candida spp. [28,29]. They 
inhibit an enzyme required for the production of ergosterol, 
which is an essential component of the fungal cytoplasmic 
membrane [28 – 30]. Fluconazole has been widely used for 
the treatment of candidiasis as it is available in intravenous 
and oral formulations, and is inexpensive, but some species 
of  Candida such as  C. krusei and  C. glabrata can exhibit 
resistance to fl uconazole [31 – 35]. 
 In this study, we fi rst demonstrated the suitability of 
MALDI-TOF MS for identifi cation of clinical fungal iso-
lates originating from Tunisian hospitals. Second, we 
determined azole susceptibility profi les of this collection 
to estimate the occurrence of resistance. Some isolates 
atypical for their susceptibility profi les were further evalu-
ated with different antifungal susceptibility methods and 
different antifungal agents. 
 Materials and methods 
 Organisms and growth conditions 
 In this study, a total of 423 yeast isolates were collected 
between September 2006 and July 2010 from three dif-
ferent hospitals in Tunisia (Hospital Habib Thameur, 
Hospital La Rabta (Tunis, the capital) and Hospital Ibn 
El Jazzar of Kairouan in central Tunisia). The yeasts were 
sequentially isolated from various clinical specimens of 
non-AIDS patients in hospitals and outpatient locations 
during the study period, including blood, other normally 
sterile body fl uids, oral cavity, gastrointestinal tract, 
respiratory tract, biomedical devices, skin, and soft tissue. 
The various specimens were obtained and processed by 
standard microbiological procedures by inoculating them 
onto Sabouraud dextrose agar supplemented with 
chloramphenicol and gentamicin and incubating at 35 ° C 
for 24 – 48 h. CHROMagar Candida plates (CHROMagar 
Candida, Paris, France) were employed for primary iden-
tifi cation of four  Candida species using the following 
criteria;  C. albicans and  C. dubliniensis    green colonies, 
 C. tropicalis    metallic blue colonies and  C. krusei    pink 
to light mauve colonies. To differentiate  C. dubliniensis 
from  C. albicans , we investigated the isolate ’ s ability to 
grow on YPDA (1% Bacto peptone [Difco Laboratories, 
Basel, Switzerland]), 0.5% yeast extract [Difco], 2% glu-
cose [Fluka, Buchs, Switzerland] and 2% agar [Difco]) at 
42 ° C.  Candida albicans ATCC 90028,  C. dubliniensis 
CBS 7987,  C. tropicalis ATCC 750, and  C. krusei ATCC 
6258 were employed as controls and it should be noted 
that for some isolates, the ID 32C yeast identifi cation 
system (bioM é rieux, Marcy l ’ Etoile, France) was used 
and the results were interpreted according to manufac-
turer ’ s instructions. 
 Identifi cation by MALDI-TOF MS 
 Identifi cation of the yeast collection by MALDI-TOF MS 
was carried out using the Microfl ex LT (Bruker Daltonics 
GmbH, Leipzig, Germany) with FlexControl (version 3.0) 
software (Bruker Daltonics) as described previously [27]. 
Briefl y, 1.5  μ l of the protein extracts were placed on steel 
target plates and allowed to dry in air, after which, each 
sample was overlaid with 1.5  μ l of matrix solution (a 
saturated solution of  α -cyano-4-hydroxycinnamic acid: 
CHCA, in 50% acetonitrile and 2.5% trifl uoracetic acid; 
Bruker Daltonik) and again air dried at room temperature. 
For standardization purposes, positive controls were 
prepared from 11 reference isolates ( C. albicans ATCC 
90028,  C. albicans ATCC 24433,  C. dubliniensis ATCC 
2118,  C. dubliniensis ATCC 2119,  C. dubliniensis CBS 
7987,  C. glabrata ATCC 90030,  C. krusei ATCC 6258, 
 C. parapsilosis ATCC 22019,  C. parapsilosis ATCC 90018, 
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 C. tropicalis ATCC 750 and  Cryptococcus neoformans 
ATCC 90112) and included in the set of analysis. The data 
were processed by the associated software and the sample 
spectra were compared to reference spectra in the provided 
database for microorganism identifi cation. Each sample 
was tested in duplicate to ensure reproducibility of the 
spectra. A characterization score cut-off value was attrib-
uted to each sample and was interpreted as recommended 
by the manufacturer. 
 Molecular species identifi cation 
 DNA of yeast cells grown overnight at 30 ° C in YPD broth 
was isolated by mechanical breakage with glass beads as 
described previously [36]. Polymerase chain reaction 
(PCR) for ITS1 – 5.8S – ITS2 and D1/D2 domains of the 
large subunits (LSU) ribosomal RNA (28S rRNA) using 
fungal primers ITS1 (5 ′ -TCCGTAGGTGAACCTGCGG-3 ′ ) 
and 26S-1 (5 ′ -GGTGAGTTGTTACACACTCC-3 ′ ) [27]. 
PCR was carried out in a total reaction volume of 50  μ l 
consisting of 200  μ M concentrations of each dNTP, 250 
nM of each primer, 1.5 mM MgCl 2 , 2.6 U of Expand High 
Fidelity PCR System (Roche, Switzerland), and 1 – 5 ng of 
total genomic DNA, according to the following conditions; 
initial denaturation at 94 ° C for 5 min followed by 35 ther-
mal cycles of 94 ° C (denaturation), 54 ° C (annealing) for 60 
s and 72 ° C (extinction) for 4 min and a fi nal elongation at 
72 ° C for 10 min on a Primus-HT PCR Systems Dualblock 
thermocycler (MWG BioTech, Ebersberg, Germany). 
A negative control was introduced by replacing the tem-
plate DNA with sterile water in the PCR mixture. The puri-
fi ed PCR products were sequenced with primers listed in 
Table 1, using an ABI prism 3130 XL automated DNA 
sequencer (Perkin Elmer, Applied Biosystems, Foster City, 
CA, USA) with a BigDye Terminator cycle sequencing kit 
(version 1.1; Applied Biosystems). Final sequences were 
assembled and edited using the software package Sequencer 
3.0 (Gene Codes Corp., Ann Arbor, MI, USA). The 
sequences of the ITS1 – 5.8S – ITS2 region and D1/D2 
domain of the 28S rRNA were submitted to the NCBI Gen-
Bank database and the accession numbers are given in 
Table 2. 
 Table 1 Primers used for sequencing of (ITS1 – 5.8S – ITS2 – D1 – D2) 
regions of nuclear ribosomal DNA. 
Primers Sequence Reference
ITS3 5 ′ -GCATCGATGAAGAACGCAGC-3 ′ [66]
ITS4 5 ′ -TCCTCCGCTTATTGATATGC-3 ′ [66]
NL1 5 ′ -GCATATCAATAAGCGGAGGAAAAG-3 ′ [66]
NL4 5 ′ -GGTCCGTGTTTCAAGACGG-3 ′ [66]
26S-5 5 ′ -AGCAGAACTGGCGATGCG-3 ′ [27]
26S-F 5 ′ -GTACAGTGATGGAAAGATGA-3 ′ [27]
 Table 2 GenBank accession numbers of the sequences of ITS1 – 5.8S –
 ITS2 region and D1/D2 domain of LSU rRNA for clinical isolates not 





JQ612155 a JEY63  Candida tunisiensis 
KC111442 JEY379  Candida palmioleophila 
KC111443 JEY380  Candida palmioleophila 
KC111444 JEY420  Debaryomyces hansenii 
KC111445 JEY258  Hanseniaspora opuntiae 
KC111446 JEY269  Hanseniaspora opuntiae 
KC111447 JEY270  Hanseniaspora opuntiae 
KC111448 JEY182  Kodamaea ohmeri 
KC111449 JEY234  Kodamaea ohmeri 
KC111450 JEY267  Pichia caribbica 
 a All rDNA includes SSU rDNA, ITS1 – 5.8S – ITS2 and LSU rDNA [27]. 
 Susceptibility testing 
 Disk diffusion  in vitro susceptibility tests to fl uconazole 
(FLC) and voriconazole (VRC) was performed as 
described by Hazen  et  al . [37] and in accordance with 
Clinical and Laboratory Standards Institute (CLSI) doc-
ument M44-A [38]. Mueller-Hinton agar supplemented 
with 2% of glucose and 0.5  μ g/ml of methylene blue 
was prepared in plates to a depth of 4.0 mm. Each isolate 
was cultured overnight at 35 ° C to ensure purity and 
viability. The inoculum was adjusted to the turbidity of 
a 0.5 McFarland standard (approximately 1 – 5    10 6 
CFU/ml) in sterile saline (0.85%) and streaked onto 
plates by using a cotton swab. FLC (25  μ g) and VRC (1 
 μ g) disks (Becton Dickinson, Sparks, MD, USA) were 
placed aseptically on the agar surface. After 24 h of 
incubation in air at 35 ° C, zone diameter endpoints were 
evaluated at 80% growth inhibition by the BIOMIC 
image analysis plate reader system (Giles Scientifi c, 
Santa Barbara, CA, USA) [37,39]. The interpretive cri-
teria for the FLC and VRC disk diffusion tests are 
described in Table 3 [40,41]. 
 Quality controls were performed with  C. albicans ATCC 
90028,  C. albicans ATCC 24433,  C. dubliniensis CBS 
7987,  C. glabrata ATCC 90030,  C. krusei ATCC 6258,  C. 
parapsilosis ATCC 22019,  C. parapsilosis ATCC 90018 
and  C. tropicalis ATCC 750. 
 The Etest (bioM é rieux) for FLC and VRC and Sensi-
titre YeastOne colorimetric (SYO) plates (TREK Diag-
nostic Systems, East Grinstead, UK) were used according 
to the manufacturer ’ s instructions. These two methods 
were only performed with isolates that were categorized 
as resistant by disk diffusion. The minimum inhibitory 
concentration (MIC) interpretive guidelines for  in vitro 
susceptibility testing for  Candida species are mentioned 
in Table 3. 
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 Results 
 Conventional species identifi cation 
 Of the total of 423 yeast isolates investigated in this study, 
206 were identifi ed with CHROMagar Candida after 24 – 
48 h of incubation as  C. albicans and/or  C. dubliniensis 
(48.7% of all isolates). The lack or highly restricted growth 
of  C. dubliniensis in 42 ° C on YPD allowed us to differen-
tiation 4.96% of all isolates in this group. Forty-eight iso-
lates (11.34%) were identifi ed as  C. tropicalis , eight isolates 
as  C. krusei (1.89%), while the rest of the collection (161 
isolates, 38.06%), was found to be atypical in terms of 
color formation and of morphologies. 
 MALDI-TOF MS identifi cation 
 In order to identify all isolates of our collection, we 
systematically screened them using the MALDI-TOF MS. 
Using a standard protein extraction protocol, correct spe-
cies level identifi cation according to the manufacturer ’ s 
criteria (cut-off score    2.00) was obtained for all reference 
strains ( C. albicans ATCC 90028,  C. albicans ATCC 
24433,  C. dubliniensis ATCC 2118,  C. dubliniensis ATCC 
2119,  C. dubliniensis CBS 7987,  C. glabrata ATCC 90030, 
 C. krusei ATCC 6258,  C. parapsilosis ATCC 22019, 
C. parapsilosis ATCC 90018,  C. tropicalis ATCC 750 and 
 Cryptococcus neoformans ATCC 90112) [27]. Correct spe-
cies level identifi cations were obtained for 97.63% (413) of 
the clinical isolates (423; for more information about level 
scores see Eddouzi et  al . [27]). Among the identifi ed iso-
lates, 84.16% showed a cut-off score    2.3, while the rest 
had a cut-off score    2.299. MALDI-TOF MS distinguished 
between  C. parapsilosis ,  C. metapsilosis and  C. orthopsi-
losis with spectral scores between 2.176 and 2.4. The dis-
tribution of yeast species identifi ed by MALDI-TOF MS 
has been already reported by Eddouzi et  al . [27]. 
 MALDI-TOF failed to identify 10 isolates given their 
low spectral scores (   1.7) and neither could they be iden-
tifi ed by ID 32 gallery tests. Since appropriate reference 
 Table 3 Clinical breakpoints for fl uconazolel (FLC) and voriconazole (VRC) as recommended by Clinical and 
Laboratory Standards Institute (CLSI) [40,41]. 
Zone diameter (mm) MIC ( μ g/ml)
S SDD R S SDD R
Species FLC VRC FLC VRC FLC VRC FLC VRC FLC VRC FLC VRC
 C. albicans    17    17 14 – 16 15 – 16    13    14    2    0.125 4 0.25 – 0.5    8    1
 C. parapsilosis    17    17 14 – 16 15 – 16    13    14    2    0.125 4 0.25 – 0.5    8    1
 C. tropicalis    17    17 14 – 16 15 – 16    13    14    2    0.125 4 0.25 – 0.5    8    1
 C. krusei  –    15  – 13 – 14  –    12  –    0.5  – 1  –    2
 C. glabrata a  –  –    15  –    14  –  –    32  –    64  – 
 S,  s usceptible; SDD,  s usceptible dose-dependent; R, resistant;  a Breakpoint was not defi ned for voriconazole. 
strains were not included in the MALDI-TOF MS instru-
ment database, we concluded that these isolates were spe-
cies rarely encountered in clinical samples or were not yet 
described. However, the ribosomal DNA of these isolates 
could used to identify nine strains distributed in fi ve spe-
cies including  Hanseniaspora opuntiae (three isolates), 
 Candida palmioleophila (two isolates),  Kodamaea ohmeri 
(two isolates),  Debaryomyces hansenii (anamorph form 
 C. famata , one isolate) and  Pichia caribbica (anamorph 
form  C. fermentati , one isolate) (see Table 2) [27]. The 
remaining isolate was identifi ed as a newly described yeast 
species:  Candida tunisiensis [27]. 
 FLC and VRC susceptibilities of the yeast collection 
 The species distribution and  in vitro susceptibilities to FLC 
and VRC determined by CLSI disk diffusion of 405  Can-
dida isolates are summarized in Table 4. The results of  in 
vitro susceptibility studies showed that FLC was most 
active against  C. albicans ,  C. parapsilosis sensu lato , 
C. tropicalis ,  C. dubliniensis ,  C. lusitaniae , C. kefyr , C. 
guilliermondii , C. utilis and  C. intermedia in 99.07% of 
cases . Decreased susceptibility to FLC was observed with 
 C. glabrata ,  C. krusei ,  C. palmioleophila and  C. guillier-
mondii . Thus, despite the fact that overall 95.56% of clin-
ical  Candida isolates were susceptible to FLC, these data 
demonstrate that the rare species ( C. palmioleophila ) 
exhibited decreased susceptibility in the range known for 
resistant species such as  C. krusei and  C. glabrata . Only 
one  C. albicans isolate (JEY355) was resistant to FLC. 
The zone of FLC growth inhibition was 13 mm and 32 mm 
for VRC. 
 VRC was considerably more active (98.51%) than FLC 
(95.56%) against all tested  Candida species, although it 
was not particularly active against isolates of  C. glabrata 
and  C. tropicalis that were already resistant to FLC. Only 
four isolates, including  C. glabrata (JEY4, JEY16 and 
JEY314) and  C. tropicalis (JEY162), exhibited cross-resis-
tance between FLC and VRC. JEY16 and JEY314 showed 
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 Table 4  Candida species distribution and  in vitro susceptibilities to fl uconazolel (FLC) and voriconazole (VRC) as determined by Clinical and 
Laboratory Standards Institute (CLSI) disk diffusion method. 
Susceptibility of isolates (%)
FLC VRC
Species




diameters (mm) S SDD R
Range of 
inhibition zone 
diameters (mm) S SDD R
 Candida albicans 185 (45.67) 13 – 41 184 (99.46) 1 (0.54) 24 – 46 185 (100)
 C. glabrata 70 (17.28) NIZ – 32 64 (91.42) 3 (4.28) 3 (4.28) NIZ – 39 66 (94.28) 1 (1.44) 3 (4.28)
 C. parapsilosis 56 (13.82) 17 – 33 56 (100) 23 – 41 56 (100)
 C. tropicalis 48 (11.85) NIZ – 34 47 (97.92) 1 (2.08) NIZ – 35 47 (97.92) 1 (2.08)
 C. dubliniensis 21 (5.18) 27 – 44 21 (100) 31 – 48 21 (100)
 C. krusei 8 (1.97) 7 – 13 8 (100) 18 – 22 8 (100)
 C. metapsilosis 5 (1.23) 19 – 23 5 (100) 28 – 31 5 (100)
 C. lusitaniae 4 (1) 30 – 41 4 (100) 38 – 46 4 (100)
 C. kefyr 2 (0.5) 34 – 38 2 (100) 37 – 41 2 (100)
 C. palmioleophila 2 (0.5) 6 – 8 2 (100) 18 – 21 1 (50) 1 (50)
 C. orthopsilosis 1 (0.25) 21 1 (100) 27 1 (100)
 C. guilliermondii 1 (0.25) 17 1 (100) 23 1 (100)
 C. utilis 1 (0.25) 30 1 (100) 33 1 (100)
 C. intermedia 1 (0.25) 36 1 (100) 40 1 (100)
Total 405 (100)  – 387 (95.56) 3 (0.74) 15 (3.7)  – 399 (98.51) 2 (0.49) 4 (0.98)
 S,  s usceptible; SDD,  s usceptible dose dependent; R, resistant; NIZ, No inhibition zone. 
 Table 5 Minimum inhibitory concentrations (MICs) for yeast isolates determined by Etest and Sensititre 
YeastOne. 
Etest ( μ g/ml) Sensititre YeastOne ( μ g/ml)
Isolate FLC VRC FLC VRC PCZ ITR KCZ 5-FC AMB CAS
JEY355 a :  Candida albicans  8 b 0.032  16 4    8  16  8 0.5 1 0.03
ATCC 90028:  Candida albicans 0.25 0.012 - - - - - - - -
JEY4:  Candida glabrata    256 4  128 4    8    16 2 0.12 1 0.25
JEY16:  Candida glabrata    256    32    256  16    8    16  8 0.12 1 0.25
JEY314:  Candida glabrata    256    32    256  16    8    16  8 0.12 1 0.25
ATCC 90030:  Candida glabrata 14 0.15 - - - - - - - -
JEY162:  Candida tropicalis    256    32    256    16    8    16  16 0.12  8 0.25
ATCC 750  Candida tropicalis 0.75 0.064 - - - - - - - -
JEY182:  Kodamaea ohmeri  24 0.25  32 0.25 0.25 1 0.12 0.06 0.5    16 
JEY234:  Kodamaea ohmeri  24 0.25  16 0.06 0.12 0.25 0.06 0.12 0.5    16 
JEY379:  C. palmioleophila    256 1  128 1 0.5 1 4 0.5 0.5 0.25
JEY380:  Candida palmioleophila  256 0.75  128 0.5 0.5 1 4 0.5 0.5 0.12
 FLC, fl uconazole; VRC, voriconazole; PCZ, posaconazole; ITR, itraconazole; KCZ, ketoconazole; 5-FC, 
5-fl ucytosine; AMB, amphotericin B; CAS, caspofungin.  a For strain references see Eddouzi  et  al . [27].  b Values 
equal or above resistance breakpoints are indicated in bold letters. 
no growth inhibition zone for the two drugs and the same 
result was observed for the  C. tropicalis isolate JEY162. 
The apparent intrinsic resistance of  C. krusei to FLC was 
not observed for VRC. VRC was active against 73.33% of 
FLC-resistant  Candida isolates. 
 Etest and Sensititre YeastOne colorimetric methods 
 The isolates that exhibited cross-resistance or susceptibil-
ity dose-dependent (SDD) profi les with FLC and VRC 
were verifi ed by two commercial methods including Etest 
and Sensititre YeastOne (SYO) plates. The MIC values for 
control and clinical strains are shown in Table 5. Etest 
showed that  C. albicans isolate JEY355 was still suscep-
tible to FLC and VRC (MIC values of 8  μ g/ml and 0.032 
 μ g/ml, respectively). Using SYO plates, JEY355 was 
SDD to FLC and resistant to VRC (MIC values of 16 and 
4  μ g/ml, respectively). High MIC values for other azoles 
were observed for JEY355 (posaconazole:    8  μ g/ml; itra-
conazole: 16  μ g/ml and ketoconazole: 8  μ g/ml). Further 
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investigations revealed that these high MICs were due to 
overexpression of  MDR1 encoding for the major facilitator 
superfamily (MFS) membrane transporter as the result 
of a new gain-of-function mutation in the zinc cluster 
transcription factor Mrr1 (data not shown). 
 Three  C. glabrata isolates (JEY16, JEY314 and JEY4) 
showed cross-resistance to FLC and VRC with high MIC 
values obtained by Etest (   256  μ g/ml). Among these 
strains, JEY16 and JEY314 exhibited high MIC values for 
VRC (   32  μ g/ml), while only 4  μ g/ml for JEY4. Both 
JEY16 and JEY314 appeared to be also more resistant to 
azole drugs as compared to JEY4 using the SYO plate 
(Table 5). 
 Among  C. tropicalis isolates, only JEY162 showed 
cross-resistance between FLC and VRC by disk diffusion 
assays, which was confi rmed by Etest and SYO plates 
(Etest MICs    256  μ g/ml for FLC and    32  μ g/ml for 
VRC). Surprisingly, JEY162 was also resistant to ampho-
tericin B (SYO MIC: 8  μ g/ml). Using molecular analysis, 
we demonstrated that JEY162 displayed alterations in 
genes involved in ergosterol biosynthesis (data not shown). 
Two clinical isolates identifi ed by molecular methods as 
 C. palmioleophila were resistant to FLC (Etest and SYO 
MICs: 256  μ g/ml and 128  μ g/ml, respectively). The disk 
diffusion test showed that two  K. ohmeri isolates were 
resistant to FLC but SDD to FLC as determined by Etest and 
SYO, respectively. In this study, we observed that  K. ohmeri 
was resistant to caspofungin (SYO MIC    16  μ g/ml), which 
so far has not been reported. The two isolates were still 
susceptible to remaining agents. 
 Discussion 
 In this work, 423 yeasts isolated from different specimens 
of Tunisian hospital patients were characterized morpho-
logically and then identifi ed by MALDI-TOF MS which is 
recommended as a reference method for yeast identifi ca-
tion [27]. CHROMagar Candida is one of the most widely 
used media in the mycology laboratory that is advertised 
as able to identify  C. albicans ,  C. krusei , and  C. tropicalis . 
With the increasing incidence of human disease being pro-
duced by the less common  Candida species, we were inter-
ested in testing the performance of this medium by 
identifying the distribution of this species in our collection. 
While MALDI-TOF MS could resolve up to 97% of the 
species in the investigated collection, this proportion was 
however only 65% for CHROMagar Candida [27], thus 
highlighting the power of MALDI-TOF MS. The results 
obtained by the chromogenic medium after 24 – 48 h of 
incubation showed correct identifi cations for  C. krusei and 
 C. tropicalis [42 – 44]. CHROMagar Candida was however 
unable to differentiate between the two related species 
 C. albicans and  C. dubliniensis , as already mentioned by 
Sahand et  al . [44]. Our fi ndings are in accordance with 
previous reports that  C. dubliniensis shows different green 
color tones that are diffi cult to differentiate from the green 
color produced by  C. albicans [42,44,45]. Growth at 42 ° C 
shows that no or highly restricted growth of all  C. dublin-
iensis isolates as compared to  C. albicans [45]. Other stud-
ies also considered CHROMagar Candida as reliable for 
the presumptive identifi cation of  C.  glabrata [43,46], 
although other researchers did not agree [42,47]. Purple, 
dark pink and violet colonies, could only be interpreted 
with precaution as presumptive  C. glabrata isolates, since 
other yeasts also grow as purple, dark pink and violet 
colonies on CHROMagar Candida [42,47,48]. 
 All  C. krusei (eight isolates, 1.9%) and  C. tropicalis 
(48 isolates, 11.34%) identifi ed by CHROMagar Candida 
were confi rmed by MALDI-TOF MS [27]. MALDI-TOF 
MS shows the ability to easily differentiate species that are 
morphologically and phylogenetically similar to each 
other. In this study, it was not diffi cult to distinguish 
between the species of  C. parapsilosis sensu lato . Among 
the  C. parapsilosis sensu lato isolates, 56 (90.32%) were 
identifi ed as  C. parapsilosis sensu stricto , 5 (8.06%) as 
 C. metapsilosis and 1 (1.61%) as  C. orthopsilosis [27]. 
These data were in agreement with previously published 
reports [21,23,26]. The specifi city of MALDI-TOF MS for 
identifying unusual yeast isolates was over 99%. In most 
cases, organisms not identifi ed by MALDI-TOF MS were 
not included in the instrument database. Consequently, 
MALDI-TOF MS did not produce any misidentifi cations, 
providing that spectra for the appropriate reference strains 
were present in the database [21,22,49]. A novel fi nding 
was the ability of MALDI-TOF MS to identify  C. glabrata 
(69/70, 98.57%),  C. parapsilosis sensu lato (57/62, 
91.93%),  C. krusei (8/8, 100%) and  C. lusitaniae (4/4, 
100%) with high spectral scores    2.3 [27]. Several studies 
have reported the effi ciency of MALDI-TOF MS for fast 
and accurate identifi cation of bacterial, yeast and mold spe-
cies [12,20 – 24,26,49]. From 10 isolates not identifi ed by 
MALDI-TOF MS, the sequencing of their ITS regions 
including 5.8S as well as D1/D2 domains of LSU rRNA 
allowed to resolve nine isolates to the species level (see 
Table 2). Only the isolate, JEY63, was identifi ed as novel 
species and was named  C. tunisiensis [27]. 
 The results of the identifi cation of our collection showed 
that the species distribution of 406  Candida isolates was 
in agreement with published studies [31,37,50]. The fi ve 
most common  Candida species including  C. albicans 
(45.56%),  C. glabrata (17.24%),  C. parapsilosis (13.79%), 
C. tropicalis (11.82%) and  C. dubliniensis (5.17%), 
accounted for 93.59% of all isolates. For non- C.  albicans 
Candida species, we observed that  C. parapsilosis pre-
ceded C. tropicalis . The same results were observed in 
North America in a study conducted between 2001 and 
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2007 and in an epidemiology study in China [50,52]. 
Recently, Diekema  et  al . [33] and Lockhart  et  al . [34] 
found the same epidemiology profi les for the four major 
 Candida species in healthcare-associated bloodstream 
infections. 
 In this work, the  in vitro susceptibility of  Candida 
species showed that the incidence of FLC resistance was 
higher than for VRC. Indeed, only one isolate of  C. albi-
cans was resistant to FLC. This was due to a new gain-
of-function mutation in the zinc cluster transcription factor 
Mrr1 [53,54], which results in the overexpression of  MDR1 . 
In addition, the decreased susceptibility to FLC was most 
pronounced in  C. glabrata and  C. krusei , which was con-
sistent with broad surveillance studies [31,33,34,37,50 – 52]. 
It is known that  C. glabrata can develop azole resistance 
at a relatively high frequency [35]. Recent fi ndings suggest 
that gain-of-function mutations in the transcription factor 
CgPdr1 are involved in the constitutive high expression of 
ABC-transporter genes ( CgCDR1 ,  CgCDR2 and  CgSNQ2 ) 
[55]. Interestingly, the azole-resistant  C. glabrata isolates 
of this study showed mitochondrial dysfunctions with the 
typical absence of growth on non-fermentable carbon 
sources such as glycerol (data not shown). Mitochondrial 
defi ciency is one of the mechanisms by which azole resis-
tance can occur in  C. glabrata [35,55 – 58].  C. glabrata 
isolates with mitochondrial dysfunctions, even if they 
exhibit strong  in vitro fi tness decrease [56], can still be 
obtained from clinical samples. Interestingly, such isolates 
may exhibit no decrease of  in vivo fi tness as compared to 
wild type isolates as suggested by Ferrari  et  al . [58], which 
could explain why they can be still recovered from 
patients. 
 Despite the increase in frequency of fungal infections 
caused by the yeast  C. tropicalis , azole resistance has been 
insuffi ciently investigated. Furthermore,  C. tropicalis 
develops drug resistance in the presence of FLC more rap-
idly than other  Candida species [59]. Our results in the 
present study showed that JEY162 was resistant to several 
azoles including FLC, VRC, posaconazole, itraconazole 
and ketoconazole. Interestingly, this isolate exhibited a 
decreased susceptibility to amphothericin B. Using a quan-
titative analysis of ergosterol, the main sterol component 
of cell membrane was typical for both a  Δ 5,6 desaturase and 
a lanosterol 14 α -demethylase defect. Using molecular 
analysis, we demonstrated that JEY162 displayed loss 
function mutations in genes encoding these enzymes  ERG3 
and ERG11 (data not shown). 
 Resistance to FLC for uncommon  Candida species 
was observed in this collection. The major species was 
C. palmioleophila , which was misidentifi ed by conven-
tional methods as C. famata or C. guilliermondii [60,61]. 
Recently, Jensen and Arendrup [60], showed that the sus-
ceptibility pattern for  C. palmioleophila was unique with 
FLC MICs in a range of 8 to    16  μ g/ml.  Candida palmi-
oleophila was ranked as susceptible or intermediate for 
itraconazole, posaconazole and VRC but was still suscep-
tible to echinocandins. In this study, the two FLC-resistant 
isolates were less susceptible to itraconazole (1  μ g/ml) and 
ketoconazole (4  μ g/ml) but still susceptible to caspofungin 
(0.12 – 0.25  μ g/ml). Many authors have found increasing 
numbers of uncommon  Candida species resistant to azole 
drugs [31,50 – 52]. Thereby, it seems relevant to assess their 
susceptibility profi les to guide the clinician for therapeutic 
decisions. 
 Previous studies have reported that  K. ohmeri was an 
emerging fungal pathogen in immunocompromised patients 
[62 – 65]. The antifungal susceptibility of the two isolates 
of this study (JEY182 and JEY234) showed SDD MICs for 
FLC but were resistant to caspofungin (MIC:    16  μ g/ml). 
In previous reports, decreased susceptibility to FLC had 
been reported together with low MICs to other echinocan-
dins (anidulafungin, micafungin and caspofungin) [62 – 65]. 
Our study is the fi rst to report caspofungin resistance in 
 K. ohmeri . Unfortunately, it cannot be determined from 
 Table 6 Correlation of susceptibility of yeast clinical isolates to azole drugs determined by three susceptibility 
methods. 










 Candida albicans JEY355 13 32 8 0.032 16 4
 C. glabrata  JEY4 NIZ 12    256 4 128 4
 C. glabrata JEY16 NIZ NIZ    256    32    256 16
 C. glabrata JEY314 NIZ NIZ    256    32    256 16
 C. tropicalis JEY162 NIZ NIZ    256    32    256 16
 Kodamaea ohmeri  JEY182 13 25 24 0.25 32 0.25
 K. ohmeri  JEY234 14 27 24 0.25 16 0.06
 C. palmioleophila  JEY379 6 15    256 1 128 1
 C. palmioleophila  JEY380 8 17 256 0.75 128 0.5
 SYO, Sensititre YeastOne; FLC, fl uconazole; VRC, voriconazole; NIZ, No inhibition zone. 
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patient records whether or not this resistance profi le was 
due to candin exposure in the patient. 
 In this work, three different methods were used to assess 
antifungal susceptibility on specifi c subset of isolates. 
Comparisons of MIC values for FLC and VRC obtained 
by Etest and SYO plate indicated a good correlation 
between obtained MICs (Table 6). One exception was for 
JEY355 which was ranked as VRC-susceptible by disk dif-
fusion and Etest methods however as VRC-resistant by 
SYO system. The results obtained for  C. glabrata and  C. 
tropicalis isolates were in agreement in all three tests. 
Some discrepancy was observed for  K. ohmeri isolates, 
which were FLC-resistant by disk diffusion, while only 
SDD by Etest and SYO plate. 
 In conclusion, our study has provided clinically useful 
data of yeast infections in Tunisia. MALDI-TOF MS was 
used as a reference method to identify clinically yeast iso-
lates. It is an advanced technique with high potential in the 
identifi cation of uncommon yeasts and permitted identifi ca-
tion of a new yeast species. MALDI-TOF MS can also give 
a robust phylogenetic approach very similar to that deduced 
from molecular methods. Examination of susceptibility of 
clinical isolates to azoles by three methods showed good 
agreement to confi rm antifungal susceptibility profi les and 
a good practical approach to provide target drugs for ther-
apy. Even if low incidence of antifungal resistance was 
observed in this work, the constant susceptibility surveil-
lance of clinical isolates is useful since it does not only 
provide important data for therapeutic decisions, but also 
provides novel specimens for in-depth molecular studies. 
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